Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tipifarnib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 533,838Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura Announces Positive Results from Registration-Directed Study of Tipifarnib
    Kura Announces Positive Results from Registration-Directed Study of Tipifarnib

    17 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/17/2761904/35186/en/Kura-Oncology-Announces-Positive-Results-from-Registration-Directed-Study-of-Tipifarnib-in-Patients-with-HRAS-Mutant-HNSCC.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib
    Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib

    24 Feb 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/kura-oncology-drops-multiple-clinical-programs-for-jj-discovered-tipifarnib/

    Paul Schloesser ENDPTS
    24 Feb 2023
    Share Share
    Kura Reports Proof of Mechanism in Phase 1/2 Trial of Tipifarnib & Alpelisib
    Kura Reports Proof of Mechanism in Phase 1/2 Trial of Tipifarnib & Alpelisib

    26 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/26/2541689/35186/en/Kura-Oncology-Reports-Preliminary-Proof-of-Mechanism-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-Plus-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html

    GLOBENEWSWIRE
    26 Oct 2022
    Share Share
    Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib
    Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib

    16 Dec 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/12/16/2353801/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-in-Combination-with-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html

    GLOBENEWSWIRE
    16 Dec 2021
    Share Share
    Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib
    Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib

    13 Dec 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/12/13/2350963/35186/en/Kura-Oncology-Reports-Final-Results-from-Phase-2-Study-of-Tipifarnib-in-T-Cell-Lymphoma.html

    GLOBENEWSWIRE
    13 Dec 2021
    Share Share
    Kura Oncology Announces Publication of Tipifarnib Ph2 Data
    Kura Oncology Announces Publication of Tipifarnib Ph2 Data

    23 Mar 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html

    GLOBENEWSWIRE
    23 Mar 2021
    Share Share